l e t t e r s
We report germline missense mutations in ETV6 segregating with the dominant transmission of thrombocytopenia and hematologic malignancy in three unrelated kindreds, defining a new hereditary syndrome featuring thrombocytopenia with susceptibility to diverse hematologic neoplasms. Two variants, p.Arg369Gln and p.Arg399Cys, reside in the highly conserved ETS DNA-binding domain. The third variant, p.Pro214Leu, lies within the internal linker domain, which regulates DNA binding. These three amino acid sites correspond to hotspots for recurrent somatic mutation in malignancies. Functional studies show that the mutations abrogate DNA binding, alter subcellular localization, decrease transcriptional repression in a dominant-negative fashion and impair hematopoiesis. These familial genetic studies identify a central role for ETV6 in hematopoiesis and malignant transformation. The identification of germline predisposition to cytopenias and cancer informs the diagnosis and medical management of at-risk individuals.
Few genes predisposing to familial myelodysplastic syndrome (MDS) and acute leukemia have been identified thus far. The genes currently known are RUNX1 (ref. 1) , CEBPA 2 , GATA2 (refs. 3,4) , ANKRD26 (refs. 5,6) and SRP72 (ref. 7) for MDS and acute myelogenous leukemia (AML) and PAX5 (refs. 8,9) and TP53 (refs. 10,11) for acute lymphoblastic leukemia (ALL). However, most cases of familial MDSleukemia remain unexplained.
We studied a family of German and Native American ancestry (family A) with genetically undefined familial thrombocytopenia and malignancy ( Fig. 1, Supplementary Fig. 1 and Supplementary Note). Exome sequencing of family members II-4, II-5, III-1, III-2 and III-3 identified five protein-altering variants-in ETV6, TOP3B, GPR144, ITGA8 and PLEC-affecting evolutionarily conserved amino acids and segregating with thrombocytopenia and malignancy under the assumption of an autosomal dominant mode of inheritance (Supplementary Table 1 ). Sanger sequencing of these five mutations in II-1 and II-3 showed that only one variant was absent in both unaffected individuals: a heterozygous germline ETV6 variant, c.1195C>T (NM_001987.4), encoding p.Arg399Cys (NP_001978.1) (Supplementary Fig. 2a ). The proband (III-2) of family A demonstrated easy bruising in infancy and menorrhagia in her teenage years. Affected members of family A also developed diverse hematologic malignancies, including MDS in III-2 at age 17 years, pre-B cell ALL in III-1 at age 7.5 years and multiple myeloma in II-5 at age 51 years (Table 1) . Additionally, subject II-5 developed stage III colorectal adenocarcinoma at age 45 years.
Targeted sequencing of ETV6 and 84 additional genes associated with bone marrow failure and MDS/AML (Supplementary Table 2 ) 12 for an additional 55 individuals with idiopathic familial leukemia or MDS (all lacking germline GATA2, RUNX1, CEBPA and PAX5 mutations) and 153 individuals with idiopathic cytopenias and/or bone marrow failure identified 2 additional families with thrombocytopenia and hematologic malignancy harboring germline ETV6 mutations. Family B, of Scottish ancestry, harbored the heterozygous ETV6 variant c.1106G>A (p.Arg369Gln) (Fig. 1) . Affected individuals in family B had thrombocytopenia with petechiae and epistaxis. Family member I-1 developed Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy l e t t e r s chronic myelomonocytic leukemia (CMML) at age 82 years. Family member III-8 was diagnosed with stage IV colon cancer at age 43 years. DNA sequencing of skin fibroblasts from the proband (II-1) of family C (Fig. 1) , of African-American ancestry, identified a heterozygous ETV6 variant, c.641C>T (p.Pro214Leu). This proband had a long history of nosebleeds and menorrhagia. She was found to have thrombocytopenia unresponsive to standard therapies for immune thrombocytopenia. At age 50 years, she developed T cell/myeloid mixed-phenotype acute leukemia (MPAL). Following standard induction chemotherapy, she had delayed recovery of both platelets and red blood cells and remained transfusion dependent for over 5 months until undergoing allogeneic hematopoietic stem cell transplantation. During this interval, she had two bone marrow biopsies without evidence of residual leukemia.
The segregation pattern for the ETV6 variants was consistent with the dominant transmission pattern of thrombocytopenia and elevated cancer risk. All individuals who carried an ETV6 variant had thrombocytopenia, and all individuals tested who developed a hematologic malignancy and/or thrombocytopenia carried an ETV6 variant (Supplementary Table 3 ).
The three ETV6 variants were absent from the public databases dbSNP139, the Exome Variant Server and the 1000 Genomes Project (see URLs). We found no germline copy number changes in ETV6 Mixed-phenotype acute leukemia (50) ITP, immune thrombocytopenia; GERD, gastrointestinal esophageal reflux disease; ALL, acute lymphoblastic leukemia; CMML, chronic myelomonocytic leukemia; RAEB-I, refractory anemia with excess blasts type I.
a Age at diagnosis in years is included in parentheses.
npg l e t t e r s in the affected family members. We also found no damaging germline mutations in RUNX1, CEBPA, GATA2, SRP72, ANKRD26, TP53 or PAX5 or in additional marrow failure-associated genes (Supplementary Table 2 ) in any of the affected individuals. ETV6 encodes the ETS family transcriptional repressor Ets variant 6. The ETV6 protein harbors a highly conserved ETS DNA-binding domain shared by all ETS family proteins. Arg369 and Arg399 reside in the second β sheet and third α helix of the ETV6 ETS domain, respectively (Fig. 2a) . Arg399 directly contacts DNA at the first guanine of the ETS binding element GGA(A/T) via bidentate hydrogen bonds (Fig. 2b) 13 . Molecular modeling of the p.Arg399Cys substitution predicted a weakened interaction with DNA 14 (Fig. 2c) . Arg369 is involved in a hydrogen bond with the backbone carbonyl oxygen of Arg414, which itself is involved in electrostatic interactions with DNA upstream of the GGA(A/T) motif 13 . Thus, the p.Arg369Gln alteration might reduce ETV6 DNA binding via destabilization of the ETS domain and/or by altering the Arg414-DNA interaction ( Supplementary Fig. 3 ). Binding of DNA by mouse Etv6 at the ETS domain is autoinhibited via a C-terminal inhibitory domain (CID; amino acids 426-436) 13, 15, 16 . The p.Pro214Leu alteration resides in a linker inhibitory domain (amino acids 127-331) that indirectly promotes DNA binding by attenuating the inhibitory effects of the CID 15 . Thus, all three encoded alterations fall within ETV6 domains affecting DNA binding. The linker domain is additionally important for the interaction of ETV6 with transcriptional corepressor complexes 17 .
We tested the effect of the ETS-domain p.Arg369Gln and p.Arg399Cys alterations on DNA binding by electrophoretic mobility shift assay (EMSA) using a DNA probe containing a consensus ETS binding site. A shift in mobility of the DNA probe was detected with Pairwise comparisons between wild-type protein and each mutant were performed using the χ 2 test (*P < 1 × 10 −48 ).
npg l e t t e r s 50 nM of the ETS domain from purified recombinant wild-type ETV6, whereas no shift was observed after the addition of up to 500 nM of the ETS domain from the Arg369Gln or Arg399Cys ETV6 mutant (Fig. 2d,e) , demonstrating that the p.Arg369Gln and p.Arg399Cys alterations abrogate DNA binding by ETV6.
Fluorescence microscopy of EGFP-tagged ETV6 in HeLa cells showed that wild-type ETV6 concentrated in cell nuclei (Fig. 3a,b) . In contrast, Pro214Leu ETV6 exhibited predominantly cytoplasmic localization and Arg369Gln and Arg399Cys ETV6 showed reduced nuclear localization (Fig. 3a,b) . Concordant with these fluorescence microscopy data, fractionation of HeLa cells transiently expressing ETV6 cDNA for the wild-type protein or the Arg399Cys mutant showed increased Arg399Cys ETV6 protein levels in the cytoplasmic fraction and decreased levels in the nuclear fraction in comparison to cells expressing the wild-type protein (Supplementary Fig. 4) . Thus, the p.Pro214Leu, p.Arg369Gln and p.Arg399Cys alterations change ETV6 localization. These results concur with previous reports that residues 332-452 at the C terminus of ETV6, which includes the ETS DNA-binding domain, affect ETV6 nuclear localization 18 . The p.Pro214Leu alteration might affect intracellular localization through indirect effects of the linker region on ETV6 DNA binding 15 . Mutations resulting in predominantly cytoplasmic localization might contribute to a dominant-negative effect via oligomerization with wild-type ETV6, resulting in its cytoplasmic sequestration. Although protein levels were comparable for exogenously expressed wild-type and mutant ETV6 proteins (Fig. 4b) , potential effects from ETV6 overexpression cannot be ruled out. Additional studies of the molecular mechanisms regulating the intracellular localization of endogenous ETV6 are warranted.
Because ETV6 functions as a transcriptional repressor of promoters harboring ETS binding sites (EBSs) 17, [19] [20] [21] [22] , we tested the effects of the ETV6 mutations on the transcriptional repression of firefly luciferase reporter constructs containing the MMP3 or PF4 promoter, which each harbor EBSs (Fig. 4a) . Whereas wild-type ETV6 repressed the expression of both reporter genes, we saw no repression with the ETV6 mutants (Fig. 4c,d) . Expression of an ETV6 ETS-domain deletion mutant has previously been shown to inhibit wild-type ETV6 transrepression in a dominant-negative manner 20 . To test whether the patient-derived missense mutations acted in a dominant-negative manner, we measured the effect of increasing the levels of mutant ETV6 cDNA, cotransfected into cells with a set quantity of wild-type ETV6 cDNA, using the PF4-firefly luciferase reporter construct. All three patient-derived mutants antagonized the repression mediated by wild-type ETV6 in a dose-dependent manner (Fig. 4e , compare bars 3-11 to bar 2).
The Pointed (PNT) domain of ETV6 mediates homo-oligomerization, a property required for stable ETV6 binding to DNA harboring tandem EBSs 15 . We hypothesized that the transrepression-defective ETV6 missense mutants inhibited transrepression by forming dysfunctional PNT domain-mediated heteromeric complexes with wild-type ETV6. We introduced into the Arg399Cys mutant the additional PNTdomain missense alterations p.Ala93Asp and p.Val112Glu, previously demonstrated to disrupt PNT-domain oligomerization 23 . In contrast to the oligomerization-competent Arg399Cys ETV6 mutant, monomeric Arg399Cys ETV6 failed to inhibit the repression mediated by wildtype ETV6 (Fig. 4e, compare bars 12-14 with bar 2) . These results suggest that dominant-negative ETV6 mutants inhibit wild-type ETV6 transrepression in an oligomerization-dependent manner.
In mouse models, Etv6 is required for hematopoietic stem cell maintenance 24 , but hematopoiesis is unperturbed by heterozygous loss of one Etv6 allele 25 . To test the effect of the dominant-negative ETV6 mutants in hematopoietic stem cells, we measured the proliferation of human CD34 + hematopoietic stem/progenitor cells (HSPCs) transduced with lentiviral vectors expressing wild-type or mutant ETV6. The proliferation of CD34 + cells expressing wild-type ETV6 was similar to that of cells receiving empty vector (Fig. 5a) . In contrast, the proliferation of CD34 + cells expressing any of the three ETV6 mutants was markedly reduced (Fig. 5a) . We noted no increase in apoptosis.
To further compare the functional consequences of the three ETV6 mutations, we performed RNA sequence (RNA-seq) profiling of the Data represent at least three individual experiments for each condition with duplicate measurements. Pairwise Student's t tests were performed comparing each condition to wild type alone (*P < 0.005, **P < 0.0005; NS, not significant).
npg l e t t e r s K562 myeloid cell line expressing wild-type, Pro214Leu, Arg369Glu or Arg399Cys ETV6. Principal-component analysis (PCA) and k-means clustering identified similar gene signature patterns for cells expressing any of the three missense mutants, which distinctly differed from the expression profiles of cells expressing wild-type ETV6 (Fig. 5b,c) . There were 311 genes whose expression was reduced by all 3 ETV6 mutants in comparison to wild-type ETV6 (Supplementary Table 4 ) and 349 genes whose expression was increased by all 3 ETV6 mutants in comparison to wild-type ETV6 (Supplementary Table 5 ). Gene Ontology (GO) analysis with GOseq identified platelet-associated gene sets that were robustly expressed with wild-type ETV6 but showed reduced expression with all three missense mutants ( Supplementary  Tables 6 and 7) . These data are consistent with the notion that all three ETV6 mutations result in similar impairment of ETV6 function.
To identify mutations acquired during malignant progression in the context of germline ETV6 mutation, we examined paired tumor and fibroblast samples from family A for mutations in 194 cancer-related genes using a targeted gene capture panel 26 . No deletion or mutation of the remaining wild-type ETV6 allele was observed in any of the neoplasms (Supplementary Fig. 2b and Supplementary Table 8) .
In individual II-5, different sets of somatic mutations were identified in the colon adenocarcinoma sample (BRAF, CTNNB1, GNAS, PTEN and TP53) than in the multiple myeloma sample (CDK8 and KMT2A) (Supplementary Table 8) . In the colon cancer sample, the BRAF mutation encoding p.Val600Glu and CTNNB1 mutations were early events, followed by mutations in GNAS and PTEN. The acquisition of multiple distinct mutations of different variant allele fractions within both GNAS and PTEN was suggestive of convergent subclonal evolution. In individual III-2, sequencing of an MDS sample upon progression to refractory anemia with excess blasts 1 (RAEB-1) identified acquired truncating mutations in BCOR and RUNX1 and an activating mutation in KRAS, all present in the same dominant clone (Supplementary Table 9 ). Sequencing of these mutations in an earlier sample taken before the development of excess blasts identified the BCOR and RUNX1 mutations, but the KRAS mutation was absent (Supplementary Fig. 5 ). This indicated that the KRAS mutation arose during progression to high-grade MDS.
Autosomal dominant transmission of thrombocytopenia and predisposition to MDS/acute leukemia caused by germline ETV6 mutations is reminiscent of phenotypes associated with mutations in RUNX1 (ref. 1) and ANKRD26 (refs. 6,27), respectively. ETV6, RUNX1 and ANKRD26 are all highly expressed in hematopoietic stem cells and megakaryocyte-erythroid progenitors 28 . Recent evidence suggests that ANKRD26 is transcriptionally regulated by RUNX1 and the ETS family transcription factor FLI1 and that autosomal dominant thrombocytopenia (THC2)-associated mutations in the 5′ UTR of ANKRD26 alter RUNX1-and FLI1-mediated regulation of ANKRD26 (ref. 29) . The potential intersection of pathways regulated by ANKRD26, RUNX1 and ETS family transcription factors in megakaryopoiesis and hematopoietic transformation warrants further study. Somatic point mutations in ETV6 have been recurrently observed by recent large-scale cancer genome sequencing efforts (Fig. 2a) [30] [31] [32] [33] [34] [35] , but the role of ETV6 mutations in malignant transformation remained unclear. We identified germline missense ETV6 mutations affecting amino acids recurrently altered across diverse malignancies (Fig. 2a) . The association of these mutations with cancer predisposition supports a role for ETV6 point mutations as initiating events in the early steps of malignant transformation. The study of familial cancer syndromes thus complements cancer genome sequencing approaches to identify driver mutations in malignancy.
URLs. dbSNP139, http://www.ncbi.nlm.nih.gov/projects/SNP/; National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project, http://evs.gs.washington.edu/EVS/; 1000 Genomes Project, http://www.1000genomes.org/.
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